№ files_lp_4_process_3_136982
File format: docx
Character count: 19305
File size: 60 KB
This document is a sample prior authorization letter for the CardioMEMS™ Heart Failure (HF) System, intended for healthcare providers to submit to insurance payers for the approval of heart failure monitoring equipment.
Year:
2022
Region / city:
United States
Topic:
Medical Prior Authorization
Document type:
Authorization Letter
Organization:
Abbott
Author:
Abbott
Target audience:
Healthcare providers, insurance payers
Effective period:
Not specified
Approval date:
2022
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
United States
Topic:
Medical Appeal, Health Coverage
Document Type:
Appeal Letter
Organization / Institution:
Abbott
Author:
Not specified
Target Audience:
Health insurance providers, medical professionals
Period of Effect:
Ongoing (until further updates)
Approval Date:
02/07/2025
Date of Modifications:
Not specified
Year:
2025
Country:
United States
Language:
English
Topic:
Heart failure management
Document type:
Sample appeal letter
Medical device:
CardioMEMS™ HF System
Clinical context:
Remote monitoring of pulmonary artery pressure
Intended use:
Insurance appeal for coverage denial
Intended audience:
Health plan appeals departments
Regulatory references:
FDA approval, CPT‡ code 93264, ICD-10, AMA, CMS
Manufacturer:
Abbott
Patient population:
NYHA Class II or III heart failure patients
Indications:
Monitoring pulmonary artery pressure and heart rate
Contraindications:
Inability to take dual antiplatelet or anticoagulants post implant
Adverse events:
Implantation-related procedural risks
Geographic applicability:
United States only
Approval date of device:
May 2014
Copyright holder:
Abbott
Version:
MAT-1900332 v5.0
Source type:
Manufacturer-provided reference and correspondence template
Note:
Year
Theme:
Medical Equipment, Adaptive Devices
Document Type:
Medical Necessity Letter
Target Audience:
Insurance Providers, Medical Professionals
Organization:
Driscoll Health Plan
Document type:
Clinical policy and administrative guidelines
Revision date:
November 1, 2024
Geographic scope:
Texas
Programs referenced:
STAR, STAR Kids, CHIP
Subject area:
Therapy services prior authorization and medical necessity
Target audience:
Therapy providers and referring physicians
Authorization method:
Provider web portal and fax submission
Related forms:
Texas Standard Prior Authorization Request Form for Health Care Services (TARF), Therapy Referral Review by Ordering Physician Attestation Form
Effective policy elements:
Initial evaluations, re-evaluations, continuation of therapy, start of care rules
Coverage criteria:
Medical necessity based on clinical documentation
Source type:
Health plan policy guideline
Year:
2021
Region / City:
United States
Topic:
Medical Necessity Letter, Health Treatment
Document Type:
Medical Document
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, healthcare providers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
California, Arizona
Topic:
Energy Transmission, Public Utilities
Document Type:
Decision
Organization / Institution:
California Public Utilities Commission
Author:
California Public Utilities Commission
Target Audience:
Stakeholders in energy infrastructure and transmission
Effective Period:
N/A
Approval Date:
November 4, 2021
Date of Changes:
N/A
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Diagnosis:
G36.0, neuromyelitis optica [Devic]
Treatment:
UPLIZNA® (inebilizumab-cdon), injection, 1 mg
Reason for request:
Medical necessity for treatment of neuromyelitis optica spectrum disorder (NMOSD) with UPLIZNA
Enclosures:
Prescribing Information, clinical notes, FDA approval letter, patient relapse history, test results, etc.
Year:
2024
Region / City:
United States
Topic:
Medical Necessity Letter
Document Type:
Medical Letter
Organization / Institution:
Bausch + Lomb
Author:
Physician
Target Audience:
Healthcare providers, Payers
Action Period:
June 2024
Approval Date:
June 2024
Modification Date:
N/A
Document type:
Medical necessity letter
Therapeutic area:
Ophthalmology
Indication:
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Medication name:
VYZULTA (latanoprostene bunod ophthalmic solution)
Dosage strength:
0.024%
Drug class:
Prostaglandin analogue with nitric oxide–donating activity
Regulatory status:
FDA-approved prescription medication
Manufacturer:
Bausch & Lomb Inc.
Intended recipient:
Health insurance payer or medical director
Target population:
Patients with open-angle glaucoma or ocular hypertension
Clinical evidence referenced:
Phase 2 VOYAGER study; Phase 3 APOLLO and LUNAR studies; real-world retrospective studies
Safety information included:
Yes
References:
Peer-reviewed journals and prescribing information
Source type:
Industry-provided informational material
Year:
2025
Region / City:
Princeton, NJ
Theme:
Medical necessity documentation
Document Type:
Medical letter
Organization / Institution:
Bristol-Myers Squibb Company
Author:
<>
Target Audience:
Healthcare professionals, physicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Jurisdiction:
West Virginia, United States
Type of document:
Legislative Act
Governing body:
West Virginia Legislature
Authors:
Delegates Riley, Linville, D. Cannon, Eldridge
Effective date:
April 11, 2025
Subject:
Public utilities regulation, water and sewer services, certificate of public convenience and necessity
Legal references:
§24-2-11, §31-15A-1 et seq. of the West Virginia Code
Scope:
Construction projects of water and sewer services for utilities with at least 4,500 customers and $3 million or more in annual revenues
Approval authority:
Public Service Commission, Infrastructure and Jobs Development Council
Decision timelines:
Standard projects 225–270 days, projects >$50 million 400 days
Year:
2023
Region / City:
United States
Subject:
Healthcare
Document Type:
Template
Institution / Organization:
Takeda Oncology
Author:
Takeda Oncology
Target Audience:
Healthcare providers, insurance companies
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Date
Year:
2026
Region / City:
N/A
Topic:
Genetic Testing, Exome Sequencing
Document Type:
Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, medical practitioners
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Program:
Illinois Early Intervention Program
State:
Illinois
Type of document:
Administrative form
Subject area:
Early intervention services
Focus:
Assistive technology justification
Target population:
Infants and toddlers enrolled in Early Intervention
Associated plan:
Individualized Family Service Plan (IFSP)
Required contributors:
Early Intervention evaluator, service coordinator, physician
Required approvals:
Physician signature
Content sections:
Demographic information, provider information, IFSP details, assessment and justification
Purpose:
Documentation of developmental necessity for assistive technology items
Note:
Year
Topic:
Medical Nutrition
Document Type:
Template Letter
Organization / Institution:
Abbott Nutrition
Author:
Physician
Target Audience:
Health Insurance Providers
Note:
Year
Author:
Martin Cowie, Saba Mian, Jessica Morris, Roger Newson, Michael Soljak, Bowen Su
Contextual description:
Technical document detailing heart failure prevalence modeling using UK primary care and hospital data, focusing on small populations.
Organisation:
Canberra Health Services
Region:
Canberra, Australian Capital Territory, Australia
Healthcare setting:
Hospital in the Home
Clinical area:
Cardiology
Condition:
Congestive cardiac failure
Patient population:
Adults
Type of document:
Clinical procedure
Route of administration:
Intravenous
Treatment:
Furosemide
Admission criteria:
Defined clinical and general eligibility requirements
Source type:
Institutional clinical guideline
Year:
2016
Region / City:
Washington, DC
Topic:
Firearm safety, technology evaluation
Document Type:
Draft
Organization / Institution:
National Institute of Justice
Author:
National Institute of Justice
Target Audience:
Firearm safety researchers, engineers, evaluators
Period of Effect:
June 2016
Approval Date:
June 2016
Modification Date:
N/A